Mymetics Corp (MYMX)

[bow-tie]

Mymetics Corp., of Epalinges, Switzerland, said it started a second preclinical study for its COVID-19 virosome-based vaccine candidates. This study, at the Helmholtz Center of Infection Research in Germany, will evaluate the safety and immunogenicity of different virosome-based COVID-19 vaccine candidates by intramuscular and intranasal administrations. The virosome formulations will incorporate and evaluate two different SARS-CoV-2 antigens, one full-length stabilized S protein, for which Mymetics is collaborating with the group of Rogier Sanders at the Amsterdam Medical Center of the University of Amsterdam, the Netherlands, and a second as a receptor binding domain recombinant protein of SARS-CoV-2.
https://www.bioworld.com/articles/499665-other-news-to-note-for-nov-2-2020

SCIENTIFIC ADVISORY BOARD Rogier Sanders
https://affiris.com/about-us/

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Rogier W. Sanders
1Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, The Netherlands
Summary
The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.
https://www.biorxiv.org/content/10.1101/2020.11.07.365726v1.full